Work

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

FWCI: 9.78
Cites: 26
Cited by: 180
Related to: 10